Efficacy and Safety of Endostar® Combined with Chemotherapy in Patients with Advanced Soft Tissue Sarcomas

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 7, 2013, Pages 4255-4259

  Zhang, Lu Ping ^a   Liao, Xing Yun ^a   Xu, Yan Mei ^a   Yan, Lv Jun ^a   Yan, Gui Fang ^a   Wang, Xin Xin ^a   Duan, Yu Zhong ^a   Sun, Jian Guo ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Antiangiogenic; Endostatin; Soft tissue sarcomas (STS); Survival analysis

Indexed keywords

ANTINEOPLASTIC AGENT; ENDOSTAR PROTEIN; ENDOSTATIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SARCOMA; SURVIVAL RATE; TUMOR RECURRENCE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; ENDOSTATINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SARCOMA; SURVIVAL RATE; YOUNG ADULT;

EID: 84885450863     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.7.4255     Document Type: Article

References (23)

1. Blay JY, Le CA, Cassier PA, et al (2012). Gastrointestinal stromal tumors (GIST): a rare entity, a tumor model for personalized therapy, and yet ten different molecular subtypes. Discov Med, 13, 357-67.
2. Brand TM, Iida M, Wheeler DL (2011). Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther, 11, 777-92.
3. Cen L, Hsieh FC, Lin HJ, et al (2007). PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound. Br J Cancer, 97, 785-91.
4. Cohen MH, Johnson JR, Chattopadhyay S, et al (2010). Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC). Oncologist, 15, 1344-51.
5. Cormier JN, Pollock RE (2004). Soft tissue sarcomas. CA Cancer J Clin, 54, 94-109.
6. Folkman J (2002). Role of angiogenesis in tumor growth and metastasis. Semin Oncol, 29, 15-8.
7. Heudel P, Cassier P, Derbel O, et al (2012). Pazopanib for the treatment of soft-tissue sarcoma. Clin Pharmacol, 4, 65-70.
8. Italiano A, Mathoulin-Pelissier S, Cesne AL, et al (2011). Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer, 117, 1049-54.
9. Jia Y, Liu M, Huang W, et al (2012). Recombinant human endostatin endostar inhibits tumor growth and metastasis in a mouse xenograft model of colon cancer. Pathol Oncol Res, 18, 315-23.
10. Jiang LP, Zou C, Yuan X, et al (2009). N-terminal modification increases the stability of the recombinant human endostatin in vitro. Biotechnol Appl Biochem, 54, 113-20.
11. Judson I (2010). Targeted therapies in soft tissue sarcomas. Ann Oncol, 21, vii277-80.
12. Kaya M, Wada T, Nagoya S, et al (2007). Prevention of postoperative progression of pulmonary metastases in osteosarcoma by antiangiogenic therapy using endostatin. J Orthop Sci, 12, 562-7.
13. Ke QH, Zhou SQ, Huang M, et al (2012). Early efficacy of Endostar combined with chemoradiotherapy for advanced cervical cancers. Asian Pac J Cancer Prev, 13, 923-26.
14. Li Y, Huang XE, Yan PW, et al (2010). Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors. Asian Pac J Cancer Prev, 11, 1119-23.
15. Olsson AK, Johansson I, Akerud H, et al (2004). The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization. Cancer Res, 64, 9012-17.
16. Purohit S, Bhise R, Appachu S, et al (2011). Systemic therapy in soft tissue sarcomas: past, present and future. Indian J Surg Oncol, 2, 327-31.
17. Reichardt P, Reichardt A, Pink D (2011). Molecular targeted therapy of gastrointestinal stromal tumors. Curr Cancer Drug Targets, 11, 688-97.
18. Riedel RF (2012). Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches. Cancer, 118, 1474-85.
19. Sasaki T, Janne PA (2011). New strategies for treatment of ALK-rearranged non-small cell lung cancers. Clin Cancer Res, 17, 7213-18.
20. Shukla NK, Deo SV (2011). Soft tissue sarcoma-review of experience at a tertiary care cancer centre. Indian J Surg Oncol, 2, 309-12.
21. th International Conference of the Asian Clinical Oncology Society (ACOS) Congress--Talk to the World Wide from Asia]. Gan To Kagaku Ryoho, 37, 2021-23.
22. Vincenzi B, Napolitano A, D Onofrio L, et al (2011). Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside. Expert Opin Investig Drugs, 20, 1685-705.
23. Wang J, Sun Y, Liu Y, et al (2005). [Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients]. Zhongguo Fei Ai Za Zhi, 8, 283-90.